vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) shares passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $18.63 and traded as low as $14.80. vTv Therapeutics shares last traded at $15.55, with a volume of 43,815 shares traded.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on VTVT shares. Wall Street Zen started coverage on vTv Therapeutics in a research note on Wednesday, April 16th. They set a "sell" rating on the stock. HC Wainwright started coverage on vTv Therapeutics in a research note on Wednesday, April 9th. They set a "buy" rating and a $36.00 price objective on the stock.
View Our Latest Stock Analysis on vTv Therapeutics
vTv Therapeutics Stock Down 4.5%
The company has a market capitalization of $49.60 million, a P/E ratio of -5.17 and a beta of 0.59. The business has a 50 day simple moving average of $18.63 and a 200-day simple moving average of $17.22.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its earnings results on Thursday, May 15th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.04).
Institutional Investors Weigh In On vTv Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after buying an additional 1,327 shares during the last quarter. Connective Capital Management LLC bought a new stake in shares of vTv Therapeutics during the first quarter valued at about $162,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the fourth quarter valued at about $25,000. 17.51% of the stock is currently owned by institutional investors.
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
